# iMMagine-3: HCP commentary report

> 307 verified statements (25 from speakers with a confirmed clinical role) from 19 commentary sources · 12 findings · updated Oct 19, 2026

## Report

- Trial: A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma
- NCT ID: NCT06413498
- Registry: https://clinicaltrials.gov/study/NCT06413498
- Sponsor: Kite, A Gilead Company
- Phase: Phase 3
- Status: Active, not recruiting
- Drugs: cyclophosphamide, fludarabine, pomalidomide, bortezomib, dexamethasone, daratumumab, carfilzomib
- Indications: Multiple myeloma
- Version: v1.0.0, edition 1
- Accepted: 2026-10-19
- Last checked: 2026-10-19
- Release hash: 854c5b50460c4251592b1eecf4c8513aa5fd750db3835cac7af4255166ea5f5e

## Counts

- HCP commentary sources screened: 21
- Sources cited by verified statements: 19
- Verified statements: 307
- From speakers with a confirmed clinical role: 25
- Findings: 12
- People found in screened sources: 10
- People identity-verified: 3
- Voices cited: 8

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

iMMagine-3 asks whether anito-cel can improve disease control compared with standard treatment options for patients with relapsed or refractory multiple myeloma. Clinicians in the sources reviewed for this edition describe CAR-T-first sequencing preferences as conditional and question the interpretation of cross-trial comparisons. They welcome response depth while treating neurological safety signals as provisional. Long-term durability, randomized benefit and earlier-line access remain unresolved in their commentary.

## Open Medical Affairs question

What would constitute persuasive randomized benefit against the standard-care options clinicians actually choose?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Randomized evidence must resolve the comparison—not cross-trial resemblance
- F2. Favorable neurological signals remain provisional and coexist with serious harms
- F3. CAR-T-first preferences depend on eligibility, treatment availability and prior target exposure
- F4. Bridging must control disease without losing the opportunity to deliver CAR-T
- F5. Costa proposes reconsidering functional high risk after modern frontline treatment
- F6. Rapid, deep responses motivate enthusiasm, but durability remains an open question
- F7. D-domain explanations offer a rationale, not proof of a clinical safety advantage
- F8. MRD is valued, but timing, assay logistics and actionability constrain its interpretation
- F9. Access requires manufacturing, referral capacity and practical support—not approval alone
- F10. Class-wide infection and delayed-toxicity concerns remain part of the CAR-T choice
- F11. Transplantation and conventional drugs retain conditional roles rather than disappearing from the sequence
- F12. Expected approval does not settle earlier-line access or long-term competitive positioning

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 23 | 22 | 15 | 7 | recorded | 4 |
| F2 | 25 | 19 | 8 | 5 | none recorded | 2 |
| F3 | 37 | 24 | 7 | 1 | recorded | 4 |
| F4 | 37 | 27 | 7 | 1 | recorded | 3 |
| F5 | 10 | 4 | 2 | 2 | none recorded | 3 |
| F6 | 43 | 24 | 11 | 5 | none recorded | 3 |
| F7 | 28 | 20 | 11 | 4 | recorded | 2 |
| F8 | 32 | 23 | 5 | 1 | recorded | 3 |
| F9 | 32 | 30 | 9 | 3 | recorded | 3 |
| F10 | 13 | 8 | 3 | 1 | recorded | 3 |
| F11 | 13 | 10 | 5 | 0 | recorded | 2 |
| F12 | 19 | 12 | 9 | 4 | recorded | 2 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 1 | 3 | 2 | 3 | 14 | 29 | 6 | 4 posts and articles, 11 podcasts and video | yes |
| F2 | 4 | 3 | 0 | 2 | 16 | 43 | 12 | 1 post or article, 7 podcasts and video | yes |
| F3 | 14 | 13 | 1 | 5 | 4 | 43 | 3 | 7 podcasts and video | yes |
| F4 | 11 | 9 | 5 | 4 | 8 | 47 | 5 | 7 podcasts and video | yes |
| F5 | 2 | 1 | 0 | 1 | 6 | 12 | 1 | 2 podcasts and video | yes |
| F6 | 7 | 6 | 1 | 3 | 26 | 85 | 14 | 11 podcasts and video | yes |
| F7 | 10 | 3 | 0 | 1 | 14 | 43 | 9 | 1 post or article, 10 podcasts and video | yes |
| F8 | 6 | 4 | 0 | 3 | 19 | 41 | 4 | 5 podcasts and video | yes |
| F9 | 3 | 1 | 3 | 1 | 24 | 47 | 11 | 2 posts and articles, 7 podcasts and video | yes |
| F10 | 1 | 2 | 3 | 3 | 4 | 18 | 3 | 3 podcasts and video | yes |
| F11 | 7 | 2 | 0 | 2 | 2 | 14 | 0 | 5 podcasts and video | yes |
| F12 | 0 | 5 | 0 | 2 | 12 | 21 | 4 | 3 posts and articles, 6 podcasts and video | yes |

### Trial dimensions

- Primary endpoint: Progression-Free Survival (PFS): F1 (3 shared claims), F6 (8 shared claims), F12 (1 shared claims)
- Primary endpoint: Minimal Residual Disease (MRD) Complete Response (CR) Rate at 9 Months: F6 (7 shared claims), F8 (2 shared claims)
- Secondary endpoints: F2 (2 shared claims), F6 (9 shared claims)
- Population and setting: F1 (2 shared claims), F2 (1 shared claims), F3 (2 shared claims), F4 (3 shared claims), F5 (3 shared claims), F6 (8 shared claims)
- The comparison: F1 (13 shared claims), F7 (1 shared claims), F9 (1 shared claims), F12 (1 shared claims)
- Safety and tolerability: F1 (1 shared claims), F2 (24 shared claims), F4 (1 shared claims), F6 (1 shared claims), F7 (2 shared claims), F10 (13 shared claims), F11 (1 shared claims), F12 (1 shared claims)
- Design and conduct: F1 (10 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

### F1. Randomized evidence must resolve the comparison—not cross-trial resemblance

An X thread addressed how differences in eligibility criteria and control treatments should enter comparisons between iMMagine-3 and CARTITUDE-4.

The account's clinical role is not stated in the sources reviewed for this edition.

Source: X thread, 2026-10-09.

### F12. Expected approval does not settle earlier-line access or long-term competitive positioning

An X account asked which three-year progression-free survival result would justify considering anito-cel comparable to Carvykti.

The account's clinical role is not stated in the sources reviewed for this edition.

Source: X thread, 2026-10-09.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 12 | Titles free |
| Detailed analysis | 15 sections | Paid |
| Verified statements with short source quotes and links | 307 | Paid |
| Trial aspects mapped | 15 | Free |
| Sources with links | 19 | Counts free |
| Speaker attribution for cited voices | 8 | Paid |

## Trial aspects

15 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Progression-Free Survival (PFS) | discussed | 12 | 6 |
| Primary endpoint: Minimal Residual Disease (MRD) Complete Response (CR) Rate at 9 Months | discussed | 9 | 5 |
| Secondary endpoints | discussed | 11 | 6 |
| Population and setting | discussed | 17 | 10 |
| The comparison | discussed | 15 | 11 |
| Safety and tolerability | discussed | 36 | 10 |
| Design and conduct | discussed | 10 | 9 |
| CAR-T versus bispecific sequencing and prior target exposure | discussed | 29 | 7 |
| Disease tempo, bridging and pre-CAR-T disease control | discussed | 25 | 7 |
| Functional high risk after contemporary frontline treatment | discussed | 10 | 2 |
| MRD assay choice, timing and clinical actionability | discussed | 27 | 4 |
| Manufacturing, outpatient delivery, referral and patient support | discussed | 30 | 9 |
| Conditional roles for transplantation and conventional therapy | discussed | 12 | 5 |
| Prospective approval, treatment-line access and positioning | discussed | 18 | 9 |
| D-domain and BCMA rationale | discussed | 26 | 11 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| YouTube | 11 | 11 |
| X threads | 8 | 6 |
| Podcasts | 2 | 2 |

- Screened window: 2024-05-13 to 2026-10-09
- Cited window: 2024-09-27 to 2026-10-09
- Retrieved: 2026-10-18

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma
- Registry: NCT06413498 (https://clinicaltrials.gov/study/NCT06413498)
- Study IDs: KT-US-679-0788 · 2024-511188-26 (European Medicines Agency) · jRCT2043240170 (Japan Registry of Clinical Trials)
- Sponsor: Kite, A Gilead Company
- Collaborators: Arcellx, Inc.
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Active, not recruiting
- Enrollment: 452 (actual)
- Start: 2024-08-23 (actual)
- Primary completion: 2028-07 (estimated)
- Primary endpoint: Progression-Free Survival (PFS) (Up to 4 years)
- Primary endpoint: Minimal Residual Disease (MRD) Complete Response (CR) Rate at 9 Months (Up to 9 months)
- Intervention: Anitocabtagene Autoleucel (drug)
- Intervention: Cyclophosphamide (drug)
- Intervention: Fludarabine (drug)
- Intervention: Pomalidomide (drug)
- Intervention: Bortezomib (drug)
- Intervention: Dexamethasone (drug)
- Intervention: Daratumumab (drug)
- Intervention: Carfilzomib (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- For 2 recordings, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.
- Some clinician views in the sources used in this report are not yet captured as evidence in this edition; the next refresh takes them up.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- Out of scope: 4 passages in the reviewed sources discuss other trials or topics outside this report's scope; they are not part of this edition.
- 361 statements in the sources reviewed for this edition discuss other treatment settings or topics unrelated to this trial's question and are not included.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- The commentary comes from 21 sources reviewed for this edition. Repeated presentations and posts may describe the same evidence or speakers; source counts do not measure the number of independent clinicians supporting a view.
- Searches emphasized study identifiers and drug-name variants. Unnamed discussions, transcription variants and relevant treatment-decision discussions without a trial reference may be missing. Some discussions centered on other CAR-T products or earlier anito-cel studies were excluded, and some passages were not fully assessed.
- Posts predating trial registration were excluded when they did not name the trial. Consequently, this edition may miss earlier views on the same relapsed/refractory treatment question.
- No protocol or results publication for NCT06413498 was available among the sources reviewed. Earlier-phase efficacy and safety observations must not be read as results of the randomized Phase 3 trial. No exact anitocabtagene autoleucel label was available to establish its current regulatory status.
- Different presentations describe different follow-up periods, evaluable populations and data updates. Response, MRD, outpatient-treatment and safety figures are not pooled or treated as interchangeable. Absence of an observed delayed event does not establish absence of risk.
- Bhella called a single-arm study requiring at least three prior lines phase 2 IMAGINE-3. That wording is preserved as her account, not adopted as the design of the registered Phase 3 study. Her description of no serious CRS is not reconciled with Kaur's report of fatal CRS in iMMagine-1.
- Two videos rely on existing transcripts, which leaves additional uncertainty about wording and speaker identity. Some passages also leave time units, response-category abbreviations, regimen boundaries or bridging proportions unclear; no unstated correction is assumed. One additional CRS passage does not establish an overall incidence clearly enough to report one.
- Some speakers and audience members cannot be identified. The unnamed X account's clinical role is unknown. Noopur Raje and Krina Patel are named in their sources, but independent documentation of their clinical roles is unavailable here. Audience experiences are kept separate from clinician assessments and formal trial outcomes.
- Some potentially relevant discussion of worldwide access and alternative in-vivo or dual-target CAR-T approaches is incomplete. Missing prior-treatment details and safety qualifications prevent a complete comparison of those alternatives.
- A first-line efficacy and tolerability discussion involving an unidentified treatment is not used as evidence for the relapsed/refractory decision. The answer to the MRD quality-of-life question uses DARA-VRD transplant/non-transplant studies only as context for that exchange, not as RRMM or iMMagine-3 evidence. Other frontline quadruplet examples are likewise not used to imply effects in iMMagine-3.
- Approval forecasts, expected decision dates, funding descriptions and local access statements reflect the speaker's time and jurisdiction. They do not establish current approval, availability or a subsequent change in clinical opinion.
- Parts of Freeman's own construct explanation and Phase 1 durability discussion, as well as portions of future sequencing, combination-treatment and daratumumab-positioning discussions, are not fully represented. Other speakers' accounts cannot substitute for those views, so this edition may miss additional rationales, qualifications or development questions.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-19: current edition, corrected 2026-10-19
  - Correction 2026-10-19: Report description rewritten to say where clinicians' views stand, not only what they discuss

Last checked for new commentary 2026-10-19. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Deep (307 verified statements)
- Current edition: $1,950. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $3,400
- 6 months of weekly updates: $4,900
- 12 months of weekly updates: $6,800
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (3 now), at most $1,950; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/immagine-3-nct06413498
- Agents: POST https://www.erudio.com/api/orders with {"report": "immagine-3-nct06413498", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=immagine-3-06413498

## Cite

Erudio Health. iMMagine-3 (NCT06413498): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 19, 2026. https://www.erudio.com/reports/immagine-3-nct06413498

## Machine access

- JSON: https://www.erudio.com/reports/immagine-3-nct06413498.json
- Markdown: https://www.erudio.com/reports/immagine-3-nct06413498.md
- MCP: https://mcp.erudio.com/mcp, tool `get_report_card` with `{"slug": "immagine-3-06413498"}`